Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ostene is a synthetic, water-soluble bone hemostasis material composed of alkylene oxide copolymers. Developed by Ceremed and marketed by Baxter Healthcare, it is designed to control bleeding from bone surfaces during surgical procedures, including cardiac, orthopedic, and neurosurgical operations. Unlike traditional bone wax, which is composed of beeswax and can interfere with bone healing, Ostene is non-thrombogenic and resorbs within 24 to 48 hours. This rapid resorption profile prevents the material from acting as a permanent foreign body, thereby reducing the risk of chronic inflammation or infection and allowing for natural osteogenesis. It functions primarily as a mechanical barrier that plugs the pores of cancellous bone to achieve immediate hemostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ostene.